Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BLUEBIRD BIO, INC.
06/11BLUEBIRD BIO INVESTIGATION INITIATED : Kahn Swick & Foti, LLC Investigates the O..
BU
06/11BLUEBIRD BIO  : Across Phase 3 studies, 89% (32/36) of evaluable patients across..
PU
06/11BLUEBIRD BIO  : betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for &b..
BU
06/07BLUEBIRD BIO  : to Present at Goldman Sachs Global Healthcare Conference
BU
06/07BLUEBIRD BIO  : Says FDA Has Lifted Clinical Hold For Studies Evaluating Investi..
MT
06/07BLUEBIRD BIO  : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disea..
PU
06/07BLUEBIRD BIO  : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disea..
BU
06/02INSIDER TRENDS : Bluebird Bio Insider Receives Stock Award, Buy Trend Intact
MT
06/02BLUEBIRD BIO, INC.  : Reports Inducement Grants to CCO Tom Klima Under Nasdaq Li..
BU
05/21BLUEBIRD BIO  : May See Momentum for Gene Therapy With EMA's Positive Opinion fo..
MT
05/21BLUEBIRD BIO  : EMA Panel Issues Positive Opinion on bluebird bio's Gene Therapy..
MT
05/21BLUEBIRD BIO  : Among 51 patients treated with SKYSONA across clinical studies t..
PU
05/21BLUEBIRD BIO  : Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene ..
BU
05/19BLUEBIRD BIO  : Analysis of characteristics of neurotoxicity (NT) observed in Ka..
PU
05/13BLUEBIRD BIO  : to Present Data from Its Severe Genetic Disease and Oncology Por..
BU
More most relevant news
All news about BLUEBIRD BIO, INC.
06/17BLUEBIRD BIO, INC.  : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/11BLUEBIRD BIO INVESTIGATION INITIATED : Kahn Swick & Foti, LLC Investigates the O..
BU
06/11BLUEBIRD BIO  : Across Phase 3 studies, 89% (32/36) of evaluable patients across..
PU
06/11BLUEBIRD BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/11BLUEBIRD BIO  : betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for &b..
BU
06/07BLUEBIRD BIO  : to Present at Goldman Sachs Global Healthcare Conference
BU
06/07BLUEBIRD BIO  : Says FDA Has Lifted Clinical Hold For Studies Evaluating Investi..
MT
06/07BLUEBIRD BIO  : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disea..
PU
06/07BLUEBIRD BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/07BLUEBIRD BIO  : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disea..
BU
More news
News in other languages on BLUEBIRD BIO, INC.
05/11PTA-NEWS : Medigene AG: Medigene informiert über Q1 2021
04/10PTA-NEWS : Medigene AG: Identifizierung von zehn neuartigen Tumor-spezifischen A..
04/10PTA-NEWS : Medigene AG: AACR-Daten zeigen Eigenschaften von Medigenes führendem ..
03/30PTA-NEWS : Medigene AG: Wissenschaftliches Paper über den Co-Rezeptor-unabhängig..
03/29USA: Les valeurs à suivre à Wall Street
03/25PTA-NEWS  : Medigene AG: Medigene berichtet über Geschäftsjahr 2020 und veröffen..
03/10PTA-NEWS  : Medigene AG: Poster auf dem AACR 2021 Annual Meeting
2018ORIGINAL-RESEARCH : Medigene AG (von EQUITS GmbH): Kaufen
2018ORIGINAL-RESEARCH : Medigene AG (von EQUITS GmbH): Kaufen
2018BLUEBIRD BIO  : gibt im New England Journal of Medicine veröffentlichte Zwischen..
More news
Analyst Recommendations on BLUEBIRD BIO, INC.
04/19BLUEBIRD BIO  : Morgan Stanley Adjusts Price Target on bluebird bio to $36 From ..
MT
03/29BLUEBIRD BIO  : Goldman Sachs Adjusts bluebird bio PT to $64 From $59, Maintains..
MT
03/29BLUEBIRD BIO  : Mizuho Securities Adjusts bluebird bio PT to $70 From $69, Maint..
MT
03/29BLUEBIRD BIO  : Piper Sandler Adjusts Bluebird Bio's Price Target to $35 From $3..
MT
03/29BLUEBIRD BIO  : SVB Leerink Adjusts Bluebird Bio's Price Target to $72 From $69,..
MT
More recommendations
Press releases
06/17BLUEBIRD BIO, INC.  : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/11BLUEBIRD BIO INVESTIGATION INITIATED : Kahn Swick & Foti, LLC Investigates the O..
BU
06/11BLUEBIRD BIO  : Across Phase 3 studies, 89% (32/36) of evaluable patients across..
PU
06/11BLUEBIRD BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/11BLUEBIRD BIO  : betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for &b..
BU
More press releases
Upcoming event on BLUEBIRD BIO, INC.
08/04/21